MediLink Therapeutics

Executive Summary

MediLink Therapeutics is a privately held Chinese biotech company pioneering next-generation antibody-drug conjugates (ADCs) through its proprietary TMALIN® platform. Founded in 2020 and headquartered in Suzhou, the company has rapidly advanced to Phase 3 clinical development, focusing on solid tumors with high unmet medical needs. TMALIN® enables ADCs with an improved therapeutic window and robust intellectual property, positioning MediLink as a potential leader in the highly competitive ADC space. With $70 million in total funding and a team of 200–500 employees, the company is advancing multiple candidates targeting validated oncology pathways, aiming to deliver best-in-class therapies that balance efficacy and tolerability. MediLink's clinical-stage pipeline is anchored by a lead ADC candidate in Phase 3 trials for a major solid tumor indication, with data readouts expected in late 2026. The company's strategy combines internal development with strategic partnership opportunities, leveraging TMALIN® for co-development and licensing. While specific financials and valuation remain undisclosed, MediLink's progress and platform technology have attracted significant investor interest. Upcoming catalysts include pivotal Phase 3 data, potential platform partnerships, and expansion of its pipeline into earlier-stage programs, which could drive near-term value inflection and establish MediLink as a key player in the global ADC landscape.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line data for lead ADC candidate60% success
• Q3 2026Strategic partnership or licensing deal for TMALIN platform50% success
• Q2 2026IND clearance for next-generation ADC program70% success